ONCOLYTICS BIOTECH INC (ONCY) Stock Profile — Insider Trades & Financials

EPS$-0.30

Market Cap$105.2M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Jared Kelly

CEO & Executive Director

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Founded: 1998
Employees: 28
Headquarters: Calgary, AB T2R 0C5, Canada

⚡

Core Efficiency

D/E Ratio?

-3.00

📊

Profitability Ratios

Current Ratio?

1.12

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 22, 2026 (in 135 days)

Annual Report (10-K) — Estimated

Aug 22, 2026

Predicted10-K

Mar 30, 2026

10-KQ4 20257d after period end

Data Freshness

Financial Data

4 days ago

Latest filing: 2026-03-30

SEC Metadata

17 days ago